Tag: Human Papillomavirus (HPV)
mRNA Assay Less Sensitive Than DNA Assay for Latent HPV
A 69.3 percent difference was seen in HPV mRNA results compared with previous HPV DNA results
Bundled Intervention May Improve HPV Vaccination Rates
Intervention included QI training, provider prompts, communication training, performance feedback
HPV Vaccine Intervention Tied to Increased Vaccination
Clinician intervention includes communication training, fact sheets, parent education site
HPV Prevalence 4.9 Percent in Tonsil Tissue of Healthy Adults
Human papillomavirus colocalizes to the biofilm of the tonsillar crypts
Reducing Tx May Harm Safety in Early HPV+ Oropharyngeal Cancer
For patients with stage III disease, intensification to triple-modality therapy may improve survival
Sex, Race, Age Disparities in Survival for HPV-Linked Cancer
Whites have consistently higher five-year survival than blacks for all cancers across all age groups
Risk of ≥CIN3 Drops With Negative HPV, Cytology Co-Tests
Decrease in 5-year ≥CIN3 risks after each successive negative round of HPV, cytology co-testing
HPV Vaccine Tied to Reduced Respiratory Papillomatosis Rate
Reduction in incidence of juvenile-onset recurrent respiratory papillomatosis from 2012 to 2016
Oncogenic Oral HPV DNA Detected in 3.5 Percent of Adults
Prevalence of oncogenic oral HPV higher in men, rises with number of lifetime oral sexual partners
Prevalence of Oral HPV Infection Higher for U.S. Men
Overall prevalence 11.5 percent in men, 3.2 percent in women; high-risk HPV also more prevalent in men
